Exciting times at #Meitheal & lots of new opportunities! 'The licensing agreement for XENLETA® adds a third branded biopharmaceutical and first on-market branded product to Meitheal’s portfolio, reinforcing Meitheal's mission to empower healthcare providers with comprehensive options to enhance patient outcomes.'
BREAKING NEWS: Meitheal Pharmaceuticals, Inc. secures exclusive commercial rights to XENLETA® (Lefamulin acetate) in the United States. Meitheal is thrilled to announce that it is further expanding its specialty biopharmaceutical portfolio by securing exclusive commercial rights in the United States to XENLETA® (Lefamulin acetate) through an exclusive license and supply agreement with its parent company, Hong Kong King-Friend Industrial Co., Ltd. XENLETA® belongs to a new class of novel antibiotics and is approved in the US for the treatment of community-acquired bacterial pneumonia (CABP) in adults. “The licensing of XENLETA® bolsters our portfolio of novel antibiotics and reflects our focus on addressing the growing issue of antimicrobial resistance,” said Tom Shea, Chief Executive Officer of Meitheal. “As the first approved medicine of an entirely new class of antibiotics, XENLETA® is an innovative therapeutic option that will be available to the patients affected by CABP and has been shown to be active against various bacterial strains. We look forward to leveraging our end-to-end expertise in biopharmaceutical development and commercialization to bring this important therapeutic to patients in need.” The licensing agreement for XENLETA® adds a third branded biopharmaceutical and first on-market branded product to Meitheal’s portfolio, reinforcing Meitheal's mission to empower healthcare providers with comprehensive options to enhance patient outcomes. Learn more about what is on the horizon at Meitheal in today’s news release: https://lnkd.in/gs22Vs8F Think sustainability, think Meitheal. #Biosimilars #HealthcareInnovation #PatientAccess #MeithealPharma #Biopharma